viewGenprex, Inc.

Full interview: Genprex's active drug ingredient validated by independent medical journal 'Nature Medicine'

Genprex (NASDAQ:GNPX) CEO Rodney Varner tells Proactive that the active ingredient in the biotech firm's immunogene therapy Oncoprex has been shown to prevent tumor growth in triple-negative breast cancer patients by an independent researcher.

Varner notes the study was published in the medical Journal “Nature Medicine”, a widely respected publication in the medical community, where he says researchers found that the gene TUSC2, the lead component of the drug, acts as a tumor-preventing gene.

Quick facts: Genprex, Inc.

Price: 2.57 USD

Market: NASDAQ
Market Cap: $84.42 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Genprex, Inc. named herein, including the promotion by the Company of Genprex, Inc. in any Content on the Site, the Company receives from said...



Full interview: Genprex makes key hires to its board and executive team

Genprex Inc (NASDAQ:GNPX) CEO Rodney Varner tells Proactive the gene therapy group has made a few key hires despite the economic downturn due to the coronavirus. Varner says the biotech has bolstered its board with three new directors, in addition to appointing two life sciences executives,...

2 days, 12 hours ago

2 min read